Please use this identifier to cite or link to this item: http://hdl.handle.net/10316/31133
DC FieldValueLanguage
dc.contributor.authorLeal, E.C.-
dc.contributor.authorSantiago, A.R.-
dc.contributor.authorAmbrósio, A.F.-
dc.date.accessioned2016-05-02T17:20:35Z-
dc.date.available2016-05-02T17:20:35Z-
dc.date.issued2005-08-
dc.identifier.issn1389-4501-
dc.identifier.urihttp://hdl.handle.net/10316/31133-
dc.description.abstractDiabetic Retinopathy (DR) is a major complication of diabetes and is a leading cause of blindness in western countries. DR has been considered a microvascular disease, and the blood-retinal barrier breakdown is a hallmark of this disease. The available treatments are scarce and not very effective. Despite the attempts to control blood glucose levels and blood pressure, many diabetic patients are affected by DR, which progresses to more severe forms of disease, where laser photocoagulation therapy is needed. DR has a huge psychological impact in patients and tremendous economic and social costs. Taking this into account, the scientific community is committed to find a treatment to DR. Understanding the cellular and molecular mechanisms underlying the pathogenesis of DR will facilitate the development of strategies to prevent, or at least to delay the progression of the disease. The involvement of the polyol pathway, advanced glycation end products, protein kinase C and oxidative stress in the pathogenesis of DR is well-documented, and several clinical trials have been conducted to test the efficacy of various drugs. More recent findings also demonstrate that DR has characteristics of chronic inflammatory disease and neurodegenerative disease, which increases the opportunity of intervention at the pharmacological level. This review presents past and recent evidences demonstrating the involvement of different molecules and processes in DR, and how different approaches and pharmacological tools have been used to prevent retinal cell dysfunction.por
dc.description.sponsorshipFundação para a Ciência e Tecnologia (FCT) e FEDERpor
dc.language.isoengpor
dc.publisherBentham Science Publisherspor
dc.rightsopenAccesspor
dc.subjectRetinopatia diabéticapor
dc.subjectBarreira hemato-retinianapor
dc.subjectProteína Quinase Cpor
dc.subjectStresse oxidativopor
dc.subjectInflamaçãopor
dc.subjectProdutos finais de glicosilação avançadapor
dc.subjectDegeneração neuronalpor
dc.titleOld and new drug targets in diabetic retinopathy: from biochemical changes to inflammation and neurodegenerationpor
dc.typearticlepor
degois.publication.firstPage421por
degois.publication.lastPage434por
degois.publication.issue4por
degois.publication.titleCurrent Drug Target - CNS & Neurologicalpor
dc.peerreviewedYespor
degois.publication.volume4por
item.languageiso639-1en-
item.grantfulltextopen-
item.fulltextCom Texto completo-
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais
Files in This Item:
File Description SizeFormat
Ambrosio AF 2005.pdf162.77 kBAdobe PDFView/Open
Show simple item record

Page view(s)

209
checked on Oct 15, 2019

Download(s) 50

301
checked on Oct 15, 2019

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.